drug dev

Sanofi’s injectable drug lixisenatide (trade name Adlyxin) has been approved by the U.S. Food and Drug Administration for treatment of adults with type 2 diabetes, the company announced. Lixisenatide is a once-daily glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of adult patients with type 2 diabetes mellitus as an adjunct to diet and… Read more